Jushi Holdings (JUSHF) Net Income towards Common Stockholders (2021 - 2026)
Jushi Holdings' (JUSHF) quarterly Net Income towards Common Stockholders came in at -$19.8 million in Q1 2026, down 16.64% year-on-year from -$23.8 million in Q1 2025, and down 27.58% on a QoQ basis from -$15.6 million in Q4 2025.
Jushi Holdings (JUSHF) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Jushi Holdings (JUSHF) has 6 years of Net Income towards Common Stockholders data on file, last reported at -$19.8 million in Q1 2026.
- On a quarterly basis, Net Income towards Common Stockholders fell 16.64% year-over-year to -$19.8 million in Q1 2026; TTM through Mar 2026 was -$71.4 million, a 50.56% decrease from a year earlier, with the FY2025 full-year figure at -$68.6 million, down 40.62% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$19.8 million, down from -$15.6 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for JUSHF reached as high as $12.1 million in Q2 2022 and fell as low as -$139.9 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$23.8 million across 5 years, with a median of -$17.0 million in 2025.
- On a YoY basis, Net Income towards Common Stockholders climbed as much as 357.74% in 2022 and fell as far as 2353.05% in 2022.
- Year by year, Net Income towards Common Stockholders stood at -$139.9 million in 2022, then surged by 87.13% to -$18.0 million in 2023, then surged by 30.75% to -$12.5 million in 2024, then retreated by 24.77% to -$15.6 million in 2025, then fell by 27.58% to -$19.8 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$19.8 million in Q1 2026, -$15.6 million in Q4 2025, and -$23.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | -2.35 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 274.90 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Jushi Holdings | 81.25 Mn | 41.54 Mn | 29.88 Mn | -19.85 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.85 Mn |
| Dec 31, 2025 | -15.56 Mn |
| Sep 30, 2025 | -23.69 Mn |
| Jun 30, 2025 | -12.33 Mn |
| Mar 31, 2025 | -17.02 Mn |
| Dec 31, 2024 | -12.47 Mn |
| Sep 30, 2024 | -16.02 Mn |
| Jun 30, 2024 | -1.94 Mn |
| Mar 31, 2024 | -18.36 Mn |
| Dec 31, 2023 | -18.00 Mn |
| Sep 30, 2023 | -20.62 Mn |
| Jun 30, 2023 | -14.04 Mn |
| Mar 31, 2023 | -12.44 Mn |
| Dec 31, 2022 | -139.94 Mn |
| Sep 30, 2022 | -54.70 Mn |
| Jun 30, 2022 | 12.07 Mn |
| Mar 31, 2022 | -19.76 Mn |
| Dec 31, 2021 | 6.21 Mn |
| Sep 30, 2021 | 39.68 Mn |
| Jun 30, 2021 | 2.64 Mn |